Janus kinase inhibitors in dermatology: Part II. A comprehensive review

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib

“… 1 , 2 Janus kinase (JAK) inhibitors are effective blockers of JAK/signal transducer and activator of transcription-mediated inflammatory signaling pathways, which regulate multiple cytokines, such as interleukins and interferons. 3 A recent case report showed hair regrowth after simultaneous treatment of AU and AD with tofacitinib, a selective inhibitor of JAK 1 and JAK 3. 4 Here, we report for the first time, to our knowledge, the clinical use of oral abrocitinib (a specific JAK 1 inhibitor) in the management of both AD and AU.…”

Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: A case report

“…Parthenium dermatitis caused by compositae weed Parthenium hysterophorus, is the commonest cause of air-borne allergic contact dermatitis in India, typically affecting face, especially the eyelids, neck, 'V' area of chest, cubital and popliteal fossa. 1 Inverse Koebner phenomenon (syn. Renbok phenomenon or isotopic nonresponse or sparing phenomenon) has been described in the literature as the absence of manifestation of a particular skin disease in an area previously affected by another skin disease or physical/ chemical insult.…”

Pharmacology of inhibitors of Janus kinases – Part 1: Pharmacokinetics

“…The JAK inhibitors mentioned can be divided into two groups: baricitinib, delgocitinib, ruxolitinib and tofacitinib may be referred to as the alpha group of JAK inhibitors; these exhibit structural similarities and have a broader pharmacological binding selectivity than representatives of the beta group (abrocitinib, deucravacitinib, filgotinib, upadacitinib). Given the ubiquity of the JAK/STAT signaling pathway and its involvement in many regulatory mechanisms, especially in inflammatory processes, the use of various JAK inhibitors has been considered or already examined in clinical trials for many chronic inflammatory diseases involving the skin [44][45][46][47]. The most comprehensive data are available for indications of atopic dermatitis [38,48,49], psoriasis and psoriatic arthritis [34,50], alopecia areata [51][52][53], hand eczema [54] and vitiligo [55].…”